IOBT Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.190

-58.24%

0.000

-100%

0.000

-100%

Estimates Revision

The market is revising No Change the revenue expectations for IO Biotech, Inc. (IOBT) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 6.23%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+6.23%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast IOBT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IOBT is 1.70 USD with a low forecast of 0.39 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

3 Hold

0 Sell

Hold

Current: 0.000

Low

0.39

Averages

1.70

High

3.00

Current: 0.000

Low

0.39

Averages

1.70

High

3.00

Morgan Stanley

Mike Ulz

Equal Weight -> Underweight

downgrade

2026-01-08

New

Reason

Morgan Stanley

Mike Ulz

Price Target

2026-01-08

New

downgrade

Equal Weight -> Underweight

Reason

Morgan Stanley analyst Mike Ulz downgraded IO Biotech to Underweight from Equal Weight with a price target of 36c, down from 39c, after the Phase 3 study for lead program, Cylembio in melanoma, failed and the FDA recommend against regulatory filing. While the firm continues to believe Cylembio may have potential, more data are needed for confirmation, which could take several years, the analyst added.

Piper Sandler

Overweight

downgrade

$10 -> $3

2025-10-22

Reason

Piper Sandler

Price Target

$10 -> $3

2025-10-22

downgrade

Overweight

Reason

Piper Sandler lowered the firm's price target on IO Biotech to $3 from $10 and keeps an Overweight rating on the shares following several updates, including recent disclosure of FDA's recommendation to not submit a BLA based on data from the pivotal study of Cylembio + pembrolizumab in 1L advanced melanoma. IO now intends to align with FDA on design of a potential new registrational study for Cylembio and still plans to discuss the data with EU regulators. Based on this news, the firm is pushing back U.S. launch in advanced melanoma to FY29.

TD Cowen

Buy

Hold

downgrade

2025-09-30

Reason

TD Cowen

Price Target

2025-09-30

downgrade

Buy

Hold

Reason

TD Cowen downgraded IO Biotech to Hold from Buy without a price target after the FDA recommended the company not file an application for Cylembio plus pembrolizumab in melanoma. IO is reducing its workforce by 50% but the company's cash \"is tight\" at $38M into Q1 of 2026, the analyst tells investors in a research note. TD cites IO's lack of late-stage catalysts for the downgrade.

Morgan Stanley

Overweight -> Equal Weight

downgrade

2025-09-30

Reason

Morgan Stanley

Price Target

2025-09-30

downgrade

Overweight -> Equal Weight

Reason

Morgan Stanley downgraded IO Biotech to Equal Weight from Overweight with a price target of 39c, down from $4, after the company announced following a pre-BLA meeting with the FDA that regulators recommended that IO Biotech not submit a BLA based on data from the Phase 3 IOB-013 clinical trial. While the firm continues to believe Cylembio has potential, the FDA requiring another Phase 3 study, combined with limited cash, increases near-term uncertainty, the analyst tells investors.

H.C. Wainwright

Emily Bodnar

Buy

Neutral

downgrade

2025-09-29

Reason

H.C. Wainwright

Emily Bodnar

Price Target

2025-09-29

downgrade

Buy

Neutral

Reason

H.C. Wainwright analyst Emily Bodnar downgraded IO Biotech to Neutral from Buy with no price target.

H.C. Wainwright

analyst

Buy -> Neutral

downgrade

2025-09-29

Reason

H.C. Wainwright

analyst

Price Target

2025-09-29

downgrade

Buy -> Neutral

Reason

As previously reported, H.C. Wainwright downgraded IO Biotech to Neutral from Buy with no price target after the company gave an update from its pre-BLA meeting with the FDA and reported that the agency does not recommend that the company submit a BLA for Cylembio. Given the company's cash position, the company would either need to raise additional capital, partner, or license out Cylembio to advance the new Phase 3 trial, says the analyst, who downgrades the shares based on the shift from a near-term regulatory review to planning a new large pivotal trial.

Valuation Metrics

The current forward P/E ratio for IO Biotech Inc (IOBT.O) is -1.19, compared to its 5-year average forward P/E of -1.41. For a more detailed relative valuation and DCF analysis to assess IO Biotech Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.41

Current PE

-1.19

Overvalued PE

-0.56

Undervalued PE

-2.25

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.25

Current EV/EBITDA

-0.60

Overvalued EV/EBITDA

1.02

Undervalued EV/EBITDA

-1.53

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

IOBT News & Events

Events Timeline

No data

News

9.0

2025-12-16NASDAQ.COM

Post-Market Winners: Biotech and Med-Tech Stocks Rise on FDA Developments, Trial Clarity, and Merger Momentum

2.0

2025-12-15Globenewswire

IO Biotech Publishes Five-Year Survival Data for Melanoma Vaccine

9.0

2025-12-15Newsfilter

IO Biotech Reports Five-Year Survival Data for Melanoma Vaccine

People Also Watch

Frequently Asked Questions

What is IO Biotech Inc (IOBT) stock price today?

The current price of IOBT is 0.5624 USD — it has increased 0.18 % in the last trading day.

What is IO Biotech Inc (IOBT)'s business?

IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.

What is the price predicton of IOBT Stock?

What is IO Biotech Inc (IOBT)'s revenue for the last quarter?

IO Biotech Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is IO Biotech Inc (IOBT)'s earnings per share (EPS) for the last quarter?

IO Biotech Inc. EPS for the last quarter amounts to -0.13 USD, decreased -63.89 % YoY.

What changes have occurred in the market's expectations for IO Biotech Inc (IOBT)'s fundamentals?

How many employees does IO Biotech Inc (IOBT). have?

IO Biotech Inc (IOBT) has 80 emplpoyees as of January 10 2026.

What is IO Biotech Inc (IOBT) market cap?

Today IOBT has the market capitalization of 40.46M USD.